COPSAC COPSAC COPSAC COPSAC
  • About COPSAC
    • About
    • Organization Diagram
    • Board of Directors
    • Research team
    • Location
    • Funding
    • Logo
    • Open positions
  • COPSAC cohorts
    • COPSAC2000 cohort
    • COPSAC2010 cohort
    • COPSACSEVERE cohort
    • COPSACACUTE cohort
    • Methods
    • Data overview
      • COPSAC2000 Clinic
      • COPSAC2000 Exposures
      • COPSAC2000 Omics
      • COPSAC2000 Biobank
      • COPSAC2010 Clinic
      • COPSAC2010 Exposures
      • COPSAC2010 Omics
      • COPSAC2010 Biobank
  • Dissemination
    • Theses
    • Literature for parents
  • Research Projects
    • RestoreGut
    • COPSYCH Research Alliance
    • HEDIMED Consortium
    • EDIAQI Consortium
    • EAGLE Consortium
    • EarlyVir
  • Strategy
  • ‌

Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

    Home Publications Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).
    NextPrevious

    Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI).

    By Dansk Børne Astma Center | Publications | Comments are Closed | 11 October, 2011 |

    Thorax. 2011 Oct
    Bel EH1, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, Wagener AH, Wagers SS, Sterk PJ, Compton CH; Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation.

    Abstract
    Patients with severe refractory asthma pose a major healthcare problem. Over the last decade it has become increasingly clear that, for the development of new targeted therapies, there is an urgent need for further characterisation and classification of these patients. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) consortium is a pan-European public-private collaboration funded by the European Commission Innovative Medicines Initiative of the European Union. U-BIOPRED aims to subphenotype patients with severe refractory asthma by using an innovative systems biology approach. This paper presents the U-BIOPRED international consensus on the definition and diagnosis of severe asthma, aligning the latest concepts in adults as well as in children. The consensus is based on existing recommendations up to 2010 and will be used for the selection of patients for the upcoming U-BIOPRED study. It includes the differentiation between ‘problematic’, ‘difficult’ and ‘severe refractory’ asthma, and provides a systematic algorithmic approach to the evaluation of patients presenting with chronic severe asthma symptoms for use in clinical research and specialised care.

    PMID: 21106547

    No tags.
    NextPrevious

    CONTACT

    COPSAC
    Copenhagen Prospective Studies on Asthma in Childhood
    Copenhagen University Hospital, Herlev-Gentofte
    phone +45 3867 7360
    contact@copsac.com
    COPSAC • Copenhagen University Hospital, Herlev-Gentofte • Denmark © 2023
    • About COPSAC
      • About
      • Organization Diagram
      • Board of Directors
      • Research team
      • Location
      • Funding
      • Logo
      • Open positions
    • COPSAC cohorts
      • COPSAC2000 cohort
      • COPSAC2010 cohort
      • COPSACSEVERE cohort
      • COPSACACUTE cohort
      • Methods
      • Data overview
        • COPSAC2000 Clinic
        • COPSAC2000 Exposures
        • COPSAC2000 Omics
        • COPSAC2000 Biobank
        • COPSAC2010 Clinic
        • COPSAC2010 Exposures
        • COPSAC2010 Omics
        • COPSAC2010 Biobank
    • Dissemination
      • Theses
      • Literature for parents
    • Research Projects
      • RestoreGut
      • COPSYCH Research Alliance
      • HEDIMED Consortium
      • EDIAQI Consortium
      • EAGLE Consortium
      • EarlyVir
    • Strategy
    • ‌
    COPSAC